Document is current

Article History

Received: 6 November 2023

Revised: 29 February 2024

Accepted: 6 March 2024

First Online: 16 March 2024

Declarations

:

: TF has received honoraria from Takeda Pharmaceutical; TT has received honoraria from Bristol Myers Squibb (BMS), Janssen Pharmaceutical, Sanofi, Kyowa Kirin, and Chugai Pharmaceutical; YS has received honoraria from Ono Pharmaceutical, BMS, Janssen Pharmaceutical, Sanofi, Kyowa Kirin, Takeda Pharmaceutical, and Chugai Pharmaceutical; SM has received honoraria from Sanofi and Ono Pharmaceutical; and NU has received honoraria from BMS and Takeda. JK is a consultant for Janssen Pharmaceutical, Pfizer, Abbvie, and BMS; has received research funding from Kyowa Kirin, Chugai Pharmaceutical, Asahikasei, Sumitomo Pharma, Otsuka Pharmaceutical, Mochida Pharmaceutical, and Japan Blood Products Organization; and has received honoraria from Janssen Pharmaceutical, Kyowa Kirin, Chugai Pharmaceutical, Ono Pharmaceutical, Sanofi, Astra Zeneca, Astellas, Eisai, Abbvie, Novartis, Daiichi Sankyo, Amgen, Otsuka Pharmaceutical, and BMS. Other authors have no conflict of interest.

: The ethics committee of each participating institute approved the study. The need to obtain informed consent from the study subjects was waived under the approval of the Ethics Committee of each institute, and we disclosed information about the study to the patients.

: Not applicable.